Tumor necrosis factor inhibitor therapy for rheumatoid arthritis

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The immunopathology of rheumatoid arthritis (RA) is now better understood, and this knowledge has been translated into more effective therapy with biologic response modifiers. The first group of biologic response modifiers are the tumor necrosis factor inhibitors. There efficacy in controlling RA has been such that remission is now the goal of RA management. As with any patient treatment, safety is an issue; patients will need ongoing monitoring for infections, tumors, and other rare complications.

Original languageEnglish (US)
Pages (from-to)709-715
Number of pages7
JournalAnnals of the New York Academy of Sciences
Volume1051
DOIs
StatePublished - 2005

Fingerprint

Patient treatment
Tumors
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Monitoring
Biological Therapy
Patient Safety
Therapeutics
Infection
Therapy
Modifier
Neoplasms
Safety
Efficacy
Remission
Complications

Keywords

  • Biologic response modifiers
  • Corticosteroids
  • Disease-modifying antirheumatic drugs
  • DMARDs
  • Rheumatoid arthritis
  • TNF-α inhibitors

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Tumor necrosis factor inhibitor therapy for rheumatoid arthritis. / Naguwa, Stanley M.

In: Annals of the New York Academy of Sciences, Vol. 1051, 2005, p. 709-715.

Research output: Contribution to journalArticle

@article{817d2125829c4d06b0daae859252cc28,
title = "Tumor necrosis factor inhibitor therapy for rheumatoid arthritis",
abstract = "The immunopathology of rheumatoid arthritis (RA) is now better understood, and this knowledge has been translated into more effective therapy with biologic response modifiers. The first group of biologic response modifiers are the tumor necrosis factor inhibitors. There efficacy in controlling RA has been such that remission is now the goal of RA management. As with any patient treatment, safety is an issue; patients will need ongoing monitoring for infections, tumors, and other rare complications.",
keywords = "Biologic response modifiers, Corticosteroids, Disease-modifying antirheumatic drugs, DMARDs, Rheumatoid arthritis, TNF-α inhibitors",
author = "Naguwa, {Stanley M}",
year = "2005",
doi = "10.1196/annals.1361.115",
language = "English (US)",
volume = "1051",
pages = "709--715",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Tumor necrosis factor inhibitor therapy for rheumatoid arthritis

AU - Naguwa, Stanley M

PY - 2005

Y1 - 2005

N2 - The immunopathology of rheumatoid arthritis (RA) is now better understood, and this knowledge has been translated into more effective therapy with biologic response modifiers. The first group of biologic response modifiers are the tumor necrosis factor inhibitors. There efficacy in controlling RA has been such that remission is now the goal of RA management. As with any patient treatment, safety is an issue; patients will need ongoing monitoring for infections, tumors, and other rare complications.

AB - The immunopathology of rheumatoid arthritis (RA) is now better understood, and this knowledge has been translated into more effective therapy with biologic response modifiers. The first group of biologic response modifiers are the tumor necrosis factor inhibitors. There efficacy in controlling RA has been such that remission is now the goal of RA management. As with any patient treatment, safety is an issue; patients will need ongoing monitoring for infections, tumors, and other rare complications.

KW - Biologic response modifiers

KW - Corticosteroids

KW - Disease-modifying antirheumatic drugs

KW - DMARDs

KW - Rheumatoid arthritis

KW - TNF-α inhibitors

UR - http://www.scopus.com/inward/record.url?scp=25444482353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444482353&partnerID=8YFLogxK

U2 - 10.1196/annals.1361.115

DO - 10.1196/annals.1361.115

M3 - Article

C2 - 16127011

AN - SCOPUS:25444482353

VL - 1051

SP - 709

EP - 715

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -